AUSTRIA and Germany will become the first markets in the European Union to launch Alzhemier’s drug Leqembi (lecanemab, Eisai).
The TGA knocked back Eisai’s application to register the anti-amyloid monoclonal antibody in Australia (PD 04 Mar), citing safety and efficacy concerns.
The post Leqembi in EU appeared first on Pharmacy Daily.
